i3 Genesis

i3 Genesis is an annual funding opportunity for early-stage healthcare technologies with clear potential for commercialization. Part of MSIP’s i3 Family of Funds, this opportunity aims to support and translate innovations by providing up to $50K to achieve value inflection points.

Innovators seeking to develop their technology with the potential for commercialization can submit to the i3 Genesis Request for Proposals (RFP) beginning February 27, 2023. Submitted proposals will first be evaluated by a review panel of experts from the MSIP Business Development team in fields including digital health, medical devices, and therapeutics. Some will be selected to pitch their proposal to the review panel during a virtual session conducted via Zoom. Proposals will be judged and scored based on project novelty, feasibility, and market risks against the budget and milestones provided. Awardees will be selected based on recorded scores and recommendations from the review panel. Funding will be disbursed to awardees once the Principal Investigator and their Administrator sign an Informed Participation Letter (IPL). More details will be provided should you be selected for i3 Genesis funding.

Are you interested in being considered for i3 Genesis and have not disclosed the technology? Disclose here.

Eligible applicants must:

Proposals involving Human Subjects or Animal Research require extra steps, such as gaining formal approval from the Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC).

For more information, please reach out to Louise Lammers, PhD, Director of Business Development, Emerging Assets at louise.lammers@mssm.edu or William Chiang, PhD, Business Development Consultant, at william.chiang@mssm.edu.